U.S. Retail Distributors Stock News

General Motors (NYSE:GM) has extended its multi year technical training partnership with V2X, Inc. through 2030. The agreement focuses on upgrading technician skills and training programs across nearly 4,000 U.S. GM dealerships. The partnership is intended to support GM's aftersales operations as vehicle technology, EVs, and connected services become more complex. For you as an investor, this move sits at the intersection of where GM aims to earn long term customer trust and where a large...

MongoDB (MDB) is back in focus after a sharp selloff, with a recent upgrade from Scotiabank helping to shift sentiment that had weakened on cautious guidance and the announced departure of two senior go to market leaders. See our latest analysis for MongoDB. At a share price of $270.56, MongoDB has seen a 7-day share price return of 7.05% after a steep 30-day share price decline of 21.43%. The 1-year total shareholder return of 38.25% contrasts with weaker year-to-date share price...

Recently, Argan highlighted progress on a large 1.4 GW combined-cycle natural gas power plant project in Texas, reaching key notice-to-proceed milestones that reinforce its role in supplying critical power infrastructure for data-center demand. At the same time, a pick-up in insider share sales adds a layer of complexity for investors weighing Argan’s growing project visibility against internal shareholder behavior. Next, we’ll examine how the Texas power project milestone and data-center...

Exxon Mobil's board has recommended relocating the company's legal domicile from New Jersey to Texas. The proposed move would align Exxon Mobil's legal home with its operating headquarters and core operations in Texas. The recommendation follows more than a century of the company being legally based in New Jersey. For shareholders watching Exxon Mobil (NYSE:XOM), the board's push to shift the legal base to Texas comes at a time when the shares trade around $148.13, with a return of 20.8%...

Why Rambus Stock Is Back in Focus Rambus (RMBS) is in the spotlight after its February 2 update on a supply chain disruption affecting Q1 2026 performance, followed by a securities law investigation that has added another source of uncertainty for shareholders. See our latest analysis for Rambus. Rambus shares have been under pressure in recent months, with a 30 day share price return of 16.3% and a 90 day share price return of 16.1%, even as the 1 year total shareholder return sits at 73.8%...

Hewlett Packard Enterprise (HPE) opened fiscal Q1 2026 with revenue of US$9.3 billion and basic EPS of US$0.32. This compares with a trailing twelve month picture that includes a basic EPS loss of US$0.18 on revenue of US$35.7 billion. Over recent quarters the company has reported revenue of US$8.5 billion in Q4 2024, US$7.9 billion in Q1 2025, US$7.6 billion in Q2 2025, US$9.1 billion in Q3 2025, US$9.7 billion in Q4 2025 and now US$9.3 billion in Q1 2026. Quarterly basic EPS has ranged from...

Bank of America reinstated coverage of Qualcomm (NasdaqGS:QCOM) with an Underperform rating, flagging multi billion dollar revenue risks tied to major customers reducing chip orders. Apple, Samsung, and Xiaomi are expected to scale back reliance on Qualcomm components over the next several years, with the analyst citing potential pressure through 2028. Qualcomm announced a new automotive AI partnership with UK based self driving startup Wayve, integrating Wayve’s driver software into the...

Roche’s persevERA Phase 3 breast cancer trial with giredestrant previously failed to meet its primary endpoint of improving progression-free survival, sparking renewed scrutiny of estrogen receptor–targeting therapies across the sector. Olema Pharmaceuticals’ separate palazestrant program, developed with Pfizer and Novartis and still in Phase 3 trials, has drawn attention as investors weigh whether its differentiated profile can set it apart from Roche’s setback. We’ll now look at how the...

Yext (YEXT) has wrapped up FY 2026 with fourth quarter revenue of US$112.0 million and basic EPS of US$0.03, alongside trailing twelve month revenue of US$446.6 million and EPS of US$0.31 that reflect its move into profitability over the past year. The company has seen quarterly revenue hold in a tight band between US$109.5 million and US$113.1 million since early FY 2026, while basic EPS has ranged from US$0.01 in Q1 to US$0.22 in Q2, a clear shift from losses in FY 2025 where quarterly EPS...

Taylor Morrison Home (NYSE:TMHC) is reporting a sharp decline in its order backlog after struggling to secure new home orders over the past two years. The company now faces expectations of lower revenue over the next 12 months, pointing to weaker demand conditions for its homebuilding operations. This shift in backlog and demand outlook marks a material change in operational momentum that has not been widely discussed yet. Taylor Morrison Home, a major US homebuilder focused on single...

If you are wondering whether Select Medical Holdings is fairly priced or offering value at today’s levels, you are not alone. This article is built to help you judge the stock through a clear valuation lens. The share price closed at US$16.26 most recently, with returns of 0.0% over 7 days, 3.6% over 30 days, 9.7% year to date, a 2.5% decline over 1 year, a 26.2% gain over 3 years, and a 6.4% decline over 5 years. This gives a mixed picture for investors weighing risk and potential...

Wondering if Hamilton Lane is attractively priced at around US$104.48, or if the market is asking too much for the shares right now? This article walks through that question step by step so you can judge the valuation for yourself. The stock has seen a 2.7% decline over the last 7 days, a 20.7% decline over the last 30 days, and a 23.5% decline year to date, while the 1 year return sits at a 24.3% decline and the 3 year and 5 year returns are 66.4% and 29.0% respectively. Those mixed results...

In February 2026, Structure Therapeutics Inc. reported fourth-quarter 2025 results showing net income of US$33 million, compared with a net loss of US$36.48 million a year earlier. On the same day, the company also filed a US$235.64 million shelf registration for 3,541,890 American Depositary Shares tied to an employee stock plan, signaling preparations for potential future capital needs. We’ll now explore how this shift to quarterly profitability, alongside the new shelf registration,...

Event context and recent price moves Fidelity National Financial (FNF) has recently seen a 2.1% one day decline, adding to a 4.5% pullback over the past week and a steeper slide over the past month and past 3 months. In this context, the stock now sits at $48.40, with trailing 1 year total return at a 16.2% decline and year to date performance also in negative territory. This may prompt investors to revisit how current pricing lines up with fundamentals. See our latest analysis for Fidelity...

Why Victoria's Secret stock is in focus after earnings and guidance Victoria's Secret (VSCO) is back in the spotlight after releasing quarterly results that exceeded earnings forecasts and paired strong sales with confident guidance for the coming quarter and full year 2026. The update has given investors fresh numbers to weigh, as the company outlines expectations for demand while also facing questions around profitability trends and ongoing decisions about its non core digital and styling...

Uranium Energy (UEC) has posted Q2 2026 revenue of US$20.2 million, with a basic EPS loss of US$0.03 and net income loss of US$13.9 million, providing a clear snapshot of where the business stands today. Over recent quarters, the company has reported revenue between US$0 and US$49.75 million while basic EPS has ranged from a loss of US$0.02 to a loss of US$0.07. This gives investors a wide view of how the top line and per-share results have shifted through different periods. With forecasts...

If you are wondering whether Western Digital's current share price still offers value after a big run, this article will walk through what the numbers are really saying about the stock. Western Digital recently closed at US$266.22, with a 6.2% return over the last 7 days, a 5.8% decline over 30 days, a 41.8% return year to date, and a very large 1-year gain of more than 5x. Recent headlines around Western Digital have focused on its position in data storage and memory solutions and how...

LifeMD (LFMD) has wrapped up FY 2025 with Q4 revenue of about US$46.9 million and basic EPS of around a US$0.04 loss, alongside trailing twelve month revenue of roughly US$194.1 million and basic EPS of about a US$0.32 loss. Over the past few reported periods, revenue has moved from US$64.3 million in Q4 2024 to US$65.7 million in Q1 2025, then US$61.1 million in Q2, US$60.2 million in Q3 and US$46.9 million in Q4. Quarterly EPS shifted from roughly a US$0.02 loss in Q4 2024 to a small profit...

Mosaic (MOS) is back in the spotlight as law firms review potential fiduciary duty issues tied to a federal probe into alleged fertilizer price fixing, raising fresh questions about legal risk and longer term shareholder exposure. See our latest analysis for Mosaic. At a share price of US$26.48, Mosaic has seen a 7.41% 1 month share price decline after legal headlines and mixed sentiment following its recent earnings report, even though the 90 day share price return of 11.49% and 1 year total...

Domino's Pizza (DPZ) is back in focus after reporting strong fourth quarter results, with global retail sales growth, positive U.S. same store sales, and a 15% dividend increase catching investor attention. See our latest analysis for Domino's Pizza. Even with the latest quarterly update and dividend increase, Domino's recent share price performance has been mixed. The 1 month share price return is 1.43%, and the 1 year total shareholder return reflects a 5.49% decline. However, the 3 year...

Prelude Therapeutics (PRLD) has just posted its FY 2025 numbers, with Q4 revenue of US$5.6 million, a basic EPS loss of US$0.21, and net income excluding extra items showing a loss of US$16.5 million. Over recent quarters the company has seen revenue move from US$4 million in Q4 2024 to US$6.5 million in Q3 2025 before landing at US$5.6 million in Q4 2025, while basic EPS has ranged from a loss of US$0.38 in Q4 2024 to a peak quarterly loss of US$0.42 in early 2025 and then US$0.21 in the...

AT&T (NYSE:T) has announced a US$250b U.S. network investment initiative tied to the 150th anniversary of the telephone. The plan targets fiber, 5G, wireless, and satellite expansion, along with workforce development and AI-focused upskilling. The company also plans new public safety and network security efforts, as well as public private collaborations across all regions. For you as an investor, this marks one of the largest infrastructure commitments ever announced by AT&T, a core player...

Wondering whether Merck's current share price really reflects its value, or if there is still room on the table for long term investors? Merck's stock closed at US$117.09 recently, with a 2.3% decline over the last 7 days and a 4.0% decline over 30 days, although the shares show returns of 10.0% year to date and 28.3% over the last year. Recent headlines around Merck have kept attention on its pipeline and broader pharmaceutical footprint. This helps frame how investors think about future...

Aurinia Pharmaceuticals (AUPH) just paired a strong 2025 earnings release with fresh 2026 guidance, outlining expectations for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million. See our latest analysis for Aurinia Pharmaceuticals. At a share price of US$14.80, Aurinia’s recent 1 day share price return of 2.99% and 7 day share price return of 4.59% follow the 1 year total shareholder return of 78.53%. This comes even though the 90 day...